Aptinyx Inc.

0.0635+0.0010+1.60%Vol 34.45K1Y Perf -77.68%
Nov 29th, 2023 15:58 DELAYED
BID0.00 ASK0.00
Open0.0600 Previous Close0.0625
Pre-Market- After-Market-
 - -  - -%
Target Price
2.25 
Analyst Rating
Hold 3.00
Potential %
3.44K 
Finscreener Ranking
★★ —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★★★     50.89
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★     44.58
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
4.72 
Earnings Rating
Neutral
Market Cap4.30M 
Earnings Date
14th Nov 2023
Alpha-0.07 Standard Deviation0.24
Beta1.30 

Today's Price Range

0.06000.0657

52W Range

0.03100.7200

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.31%
1 Month
0.00%
3 Months
-6.89%
6 Months
-10.06%
1 Year
-77.68%
3 Years
-98.40%
5 Years
-99.71%
10 Years
-

TickerPriceChg.Chg.%
APTX0.06350.00101.60
AAPL189.37-1.0300-0.54
GOOG136.40-2.2200-1.60
MSFT378.85-3.8500-1.01
XOM102.34-1.5600-1.50
WFC43.780.41000.95
JNJ152.110.48000.32
FB196.640.99000.51
GE118.860.01000.01
JPM154.320.78000.51
Financial StrengthValueIndustryS&P 500US Markets
24.70
27.40
0.34
0.51
-33.70
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
-
-7 453.40
-7 400.80
-1 884.40
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-43.34
-34.38
Earnings HistoryEstimateReportedSurprise %
Q01 2023-0.23-0.31-34.78
Q04 2022-0.19-0.185.26
Q03 2022-0.24-0.234.17
Q02 2022-0.29-0.2610.34
Q01 2022-0.31-0.296.45
Q04 2021-0.35-0.2917.14
Q03 2021-0.31-0.310.00
Q02 2021-0.25-0.29-16.00
Earnings Per EndEstimateRevision %Trend
9/2023 QR-0.050.00-
12/2023 QR-0.080.00-
12/2023 FY-0.400.00-
12/2024 FY-0.100.00-
Next Report Date-
Estimated EPS Next Report-0.05
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume34.45K
Shares Outstanding67.72K
Shares Float53.65M
Trades Count14
Dollar Volume2.15K
Avg. Volume51.09K
Avg. Weekly Volume41.07K
Avg. Monthly Volume53.86K
Avg. Quarterly Volume58.33K

Aptinyx Inc. (NASDAQ: APTX) stock closed at 0.0635 per share at the end of the most recent trading day (a 1.6% change compared to the prior day closing price) with a volume of 34.45K shares and market capitalization of 4.30M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. Aptinyx Inc. CEO is Norbert G. Riedel.

The one-year performance of Aptinyx Inc. stock is -77.68%, while year-to-date (YTD) performance is -77.74%. APTX stock has a five-year performance of -99.71%. Its 52-week range is between 0.031 and 0.72, which gives APTX stock a 52-week price range ratio of 4.72%

Aptinyx Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.53, a price-to-sale (PS) ratio of 166.58, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -69.34%, a ROC of -72.56% and a ROE of -90.04%. The company’s profit margin is -%, its EBITDA margin is -7 400.80%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Aptinyx Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. Aptinyx Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aptinyx Inc. is Hold (3), with a target price of $2.25, which is +3 443.31% compared to the current price. The earnings rating for Aptinyx Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aptinyx Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aptinyx Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.34, ATR14 : 0.00, CCI20 : 0.96, Chaikin Money Flow : 0.37, MACD : 0.00, Money Flow Index : 61.77, ROC : 1.63, RSI : 47.20, STOCH (14,3) : 70.09, STOCH RSI : 0.00, UO : 56.27, Williams %R : -29.91), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aptinyx Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.00
Hold
3.00
Hold
3.00

Aptinyx Inc.

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.

CEO: Norbert G. Riedel

Telephone: +1 847 871-0377

Address: 909 Davis Street, Evanston 60201, IL, US

Number of employees: 43

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

48%52%

Bearish Bullish

59%41%

Bearish Bullish

62%38%

 

News

Stocktwits